Stock Research: UCB

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

UCB

ENXTBR:UCB BE0003739530
66
  • Value
    29
  • Growth
    99
  • Safety
    Safety
    12
  • Combined
    42
  • Sentiment
    94
  • 360° View
    360° View
    66
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

UCB SA is a biopharmaceutical and specialty chemical company specializing in central nervous system (CNS) and immunology diseases. Its main business includes CNS disorders like epilepsy and immunology disorders such as rheumatoid arthritis. UCB SA operates globally, with a focus on Europe and North America. In the last fiscal year, the company had a market cap of $39,605 million, profits of $4,555 million, revenue of $6,369 million, and 9378 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 66 (better than 66% compared with alternatives), overall professional sentiment and financial characteristics for the stock UCB are above average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for UCB. The consolidated Growth Rank has a good rank of 99, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 99% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 94, which means that professional investors are more optimistic about the stock than for 94% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 12, which means that the share price of UCB is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 88% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 29, which means that the company has a financing structure that is riskier than those of 71% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
BEL20
Human Rights
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 9-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
12 6 79 74
Growth
99 90 89 19
Safety
Safety
29 24 24 38
Sentiment
94 61 10 38
360° View
360° View
66 37 45 30
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
64 49 36 49
Opinions Change
76 59 24 48
Pro Holdings
n/a 45 14 56
Market Pulse
78 69 47 27
Sentiment
94 61 10 38
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
12 6 79 74
Growth
99 90 89 19
Safety Safety
29 24 24 38
Combined
42 24 82 32
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
17 15 54 71
Price vs. Earnings (P/E)
15 11 46 54
Price vs. Book (P/B)
23 21 81 78
Dividend Yield
32 32 70 65
Value
12 6 79 74
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
85 94 54 6
Profit Growth
90 54 77 48
Capital Growth
67 56 76 21
Stock Returns
93 96 52 54
Growth
99 90 89 19
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
61 61 48 43
Refinancing
17 18 23 24
Liquidity
25 31 40 56
Safety Safety
29 24 24 38

Similar Stocks

Discover high‑ranked alternatives to UCB and broaden your portfolio horizons.

Tessenderlo

ENXTBR:TESB
Country: Belgium
Industry: Diversified Chemicals
Size: Medium
Full Stock Analysis

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.

BUSE:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Perrigo

NYSE:PRGO
Country: Ireland
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

thyssenkrupp

XTRA:TKA
Country: Germany
Industry: Steel
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.